Prof. Jun Ma: Key Components for Hematologic Malignancies’ Future – Medical Administration, Pharmaceuticals, and Doctor-Patient Relations | 2024 CSCO
Amidst the waves and scenic beauty, from January 26th to 28th, the "China Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, and the 2024 CSCO Hematology, Lymphoma, and Myeloma Disease Academic Conference" was grandly held in the beautiful city of Haikou. Renowned experts and scholars from both domestic and international arenas gathered to share and exchange important research findings in the fields of leukemia, lymphoma, and myeloma over the past year. They also delved into in-depth discussions on hot topics in diagnosis and treatment. Oncology Frontier - Hematology Frontier had the privilege of interviewing Professor Jun Ma, the executive chairman of this conference and director of the Harbin Institute of Hematological Tumors. He elaborated on the highlights and exciting aspects of the conference, shared insights on the significance of establishing standardized lymphoma diagnosis and treatment centers, and highlighted the working priorities of the 2024 CSCO Leukemia and Lymphoma Expert Committees.